With A Drug On The Fast Track, Chimerix Aims To Go Public
This article was originally published in The Pink Sheet Daily
Executive Summary
Once wary of the IPO market, the antiviral drug developer looks to public investors as it prepares to fund a Phase III trial for a well-regarded but unpartnered cytomegalovirus drug.